This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thompson, G. R.
Right arrow Articles by Patterson, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thompson, G. R., III
Right arrow Articles by Patterson, T. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2009, p. 309-311, Vol. 53, No. 1
0066-4804/09/$08.00+0     doi:10.1128/AAC.01216-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Antifungal Susceptibilities among Different Serotypes of Cryptococcus gattii and Cryptococcus neoformans{triangledown}

George R. Thompson III,1,6* Nathan P. Wiederhold,1,2,5,6 Annette W. Fothergill,3 Ana C. Vallor,1,6 Brian L. Wickes,4 and Thomas F. Patterson1,6

Department of Internal Medicine, Division of Infectious Diseases,1 Pharmacotherapy Education and Research Center,2 Fungus Testing Laboratory, Department of Pathology,3 Department of Microbiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas,4 The University of Texas at Austin College of Pharmacy, Austin, Texas,5 South Texas Veterans Health Care System, San Antonio, Texas6

Received 12 September 2008/ Returned for modification 11 October 2008/ Accepted 16 October 2008

We measured antifungal activity against 128 cryptococcal isolates (86 of C. neoformans and 42 of C. gattii) to determine if differences in serotype susceptibility exist. Contrary to previous results, we found no serotype susceptibility differences. Isavuconazole, posaconazole, and voriconazole demonstrated excellent potency against each isolate and serotype, including isolates with reduced fluconazole susceptibilities.

* Corresponding author. Mailing address: Department of Internal Medicine, Division of Infectious Diseases, UTHSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78229. Phone: (210) 567-6680. Fax: (210) 567-3303. E-mail: thompsong2{at}uthscsa.edu

{triangledown} Published ahead of print on 27 October 2008.

Antimicrobial Agents and Chemotherapy, January 2009, p. 309-311, Vol. 53, No. 1
0066-4804/09/$08.00+0     doi:10.1128/AAC.01216-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Thompson, G. R. III, Wiederhold, N. P., Sutton, D. A., Fothergill, A., Patterson, T. F. (2009). In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother 64: 79-83 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»